The wall every European TAA investor hits
A European retail investor opens IBKR, finds HAA on BestFolio, and clicks through to implement it. The strategy wants SPY, IWM, VWO, VEA, QQQ, IEF, TLT, DBC, plus a canary in TIP and a defensive parking spot in BIL. Nine of those tickers are US-domiciled. None of them are buyable.
The block sits at the regulator. PRIIPs requires a Key Information Document in the investor's home language for any product sold to EU retail, and US ETF issuers don't produce them. The result is that the most-cited TAA strategies are designed around a universe that European retail clients can't access through normal channels.
The workaround is UCITS substitution. Every US sleeve gets mapped to a UCITS ETF that holds roughly the same exposure, listed on XETRA or Borsa Italiana or LSE, and tradeable through any EU broker. The question is how clean that substitution actually is. The honest answer is that it depends a lot on the strategy.
What "clean substitution" actually means
Three criteria, all of which matter, all of which usually get conflated when people say "the European version":
- Asset class match. S&P 500 for S&P 500. Long treasuries for long treasuries. This is the criterion most discussions stop at.
- Methodology match. Cap-weighted vs cap-weighted, value composite vs value composite, total-market vs market-cap-1500. Two ETFs can both say "small cap value" and hold meaningfully different baskets.
- Liquidity match. The substitute has to absorb a TAA-sized order without painful spreads. A 30 to 50 basis point bid-ask on a monthly rebalancer with 200% annual turnover quietly eats 60 to 100bps of CAGR, which is a TER twice over.
The Tier 1 strategies below clear all three. Tier 2 clears one or two. Tier 3 doesn't really clear any of them, which is fine if you know that going in.
Tier 1: the strategies that translate cleanly
These five run on universes that have one-to-one UCITS substitutes with deep XETRA or LSE liquidity. If you're starting from zero in Europe, start here.
| Strategy | Universe | UCITS substitution friction |
|---|---|---|
| HAA | SPY, QQQ, IWM, VWO, VEA, IEF, TLT, DBC, plus canary TIP / BIL / IEF | One messy sleeve (DBC, see Tier 3 commodity discussion). Everything else is clean. |
| GEM | SPY, VEU, AGG, BIL | Clean. VEU substitutes to a developed-plus-EM split (IDEV + IEMG) or a single global-ex-US fund. |
| Permanent Portfolio | SPY, TLT, GLDM, BIL | Clean across all four sleeves. |
| All Weather | SPY, IEF, TLT, GLD, DBC, TIP | DBC and TIP are the wrinkles. Everything else is clean. |
| Classic 60/40 | SPY, AGG | Clean. CSPX plus IUAG covers it. |
Concrete substitutes that work right now, with their approximate total expense ratios for reference. We're not picking favorites here, several issuers offer a clean substitute for most of these:
- SPY: CSPX (iShares Core S&P 500 UCITS), TER around 0.07%
- QQQ: CNDX (iShares Nasdaq 100 UCITS), TER around 0.30%
- IEF: IBTM (iShares $ Treasury Bond 7-10yr UCITS), TER around 0.07%
- TLT: DTLA (iShares $ Treasury Bond 20+yr UCITS), TER around 0.07%
- GLD or GLDM: IGLN (iShares Physical Gold ETC, also listed as SGLN), TER around 0.12%
- AGG: IUAG (iShares Core Global Aggregate Bond UCITS, USD-hedged variants exist), TER around 0.10%
- BIL: IB01 (iShares $ Treasury Bond 0-1yr UCITS), TER around 0.07%. Keeps USD T-bill exposure for strategies that depend on it; if you want EUR cash instead, swap to CSH2 (XTrackers EUR Overnight Rate Swap), TER around 0.10%, and accept the currency shift.
The friction in this tier is mostly invisible. The S&P 500 sleeve via CSPX is arguably better than SPY for a long-term European holder, because it's accumulating (no automatic dividend payouts, no withholding cascade) and it's Irish-domiciled (15% US withholding on the underlying dividends via the treaty, no second layer of EU tax). A European running HAA via CSPX, IBTM, DTLA, IGLN often ends up with a slightly cleaner setup than the US version of the same strategy.
Tier 2: viable but you lose some character
These are the strategies whose universes include sleeves where the UCITS substitute is real but it isn't exactly the same fund. The compromise lives in the methodology, not the asset class.
Small-cap value (AVUV, IWN, IJS, VIOV, VBR). Avantis launched a UCITS lineup in late 2024-early 2025, including AVWS (Avantis Global Small Cap Value UCITS, ISIN IE0003R87OG3, TER 0.39%, on LSE + XETRA) and AVUS (Avantis US Equity). AVWS uses the same Avantis profitability-plus-value methodology, but the universe is global developed (not US-only), so it isn't a one-to-one clone of AVUV. For US-only small-cap-value exposure specifically, the closest non-Avantis substitute is SPDR's MSCI USA Small Cap Value Weighted UCITS (ticker ZPRV). Two routes from here. Route one, AVWS (Avantis global small-cap value, IE0003R87OG3): same Avantis methodology, broader universe, so the US-only character of an AVUV sleeve loosens. Route two, ZPRV (SPDR MSCI USA SCV Weighted): keeps the US-only universe but switches to MSCI value-composite weighting, which loses the Avantis profitability-plus-value tilt. The rolling 12-month correlation between AVUV and ZPRV runs in the 0.80 to 0.85 range, which means your backtested CAGR on a strategy with a 15% AVUV sleeve drifts by roughly 50 to 100bps annually if you substitute via ZPRV. That's tolerable for a low-weight sleeve. For a 30%+ AVUV allocation it stops being tolerable.
US REIT (VNQ). The cleanest UCITS substitute is iShares US Property Yield UCITS (IUSP). Methodology is close, but daily volume on XETRA is materially thinner than VNQ on US exchanges, so spreads widen for any meaningful order size. Workable for monthly rebalancing if you use limit orders.
Developed ex-US small cap (SCZ). ZPRX (SPDR MSCI Europe Small Cap Value Weighted) covers part of it. EFA-style developed ex-US large cap has clean substitutes (IDEV, EUNL). Combining the two recreates SCZ approximately but the result is a Frankenstein.
Tier 3: no clean substitute exists
These are the sleeves where the honest answer is that the European version is a different exposure.
Diversified commodity (DBC, PDBC). The active K-1-free commodity strategy that DBC and PDBC implement isn't replicable in UCITS form, because the regulatory wrapper restricts the use of futures rolls. The available substitutes (WisdomTree Enhanced Commodity UCITS, Invesco Bloomberg Commodity UCITS, UBS CMCI) are passive and weighted differently. For HAA's DBC sleeve, the practical workaround is to substitute the WisdomTree Enhanced Commodity UCITS (ticker CMOP) and accept a 100 to 200bps tracking drift over a full commodity cycle. For pure commodity-momentum strategies that depend on DBC's specific exposure (carry on the curve, weighting), the European version simply doesn't reproduce the original.
TIPS (TIP). UCITS TIPS funds exist (ITPS, Lyxor's IBCI). They hold US TIPS, so the asset class match is exact. The wrinkle is currency: a European investor holding ITPS in EUR has full USD exposure on the principal, which means the inflation-protection sleeve becomes a USD/EUR currency trade in addition to a real-rates trade. Currency-hedged variants exist but eat 30 to 50bps in hedging cost. There's no painless answer.
Active or thematic alpha sleeves (REM mortgage REITs, leveraged factor ETFs, K-1 partnerships). Mostly not available in UCITS form. Skip these strategies if your broker setup forces you onto UCITS.
The XETRA reality: even when the substitute is clean
Bid-ask matters more for TAA than buy-and-hold. A buy-and-hold investor pays the spread twice in their lifetime. A monthly TAA investor with 200% annual turnover pays it 24 times a year, and at typical XETRA spreads for thin sleeves (0.20 to 0.40% round trip on small-cap UCITS, sometimes more), the annual drag stacks up quickly.
A useful sanity check: a recent r/LETFs thread flagged WisdomTree's GDE (a capital-efficient stock-plus-gold ETF) for carrying a 30-day average bid-ask spread of 0.74%, which is a US product on US exchanges. Equivalent UCITS funds on lighter exchanges hit similar numbers on bad days. For any TAA strategy you're considering, look up the daily volume and recent spread on the actual UCITS substitute before you commit, not just the TER. The TER is the headline; the spread is the bill.
A practical rule: use limit orders on XETRA for any sleeve below ~€100M daily volume on the substitute ETF, and accept that you may not get filled on a fast-moving rebalance day. Monthly rebalancers tolerate this. Daily or weekly rebalancers don't.
Where this leaves the catalog
From the 100+ TAA strategies in the BestFolio catalog, the substitution friction maps roughly like this:
- Green: HAA, GEM, Permanent Portfolio, Classic 60/40, large-cap-only momentum variants. Translates to UCITS with negligible CAGR drift.
- Yellow: Strategies with a small-cap-value sleeve under 20% (Golden Butterfly, certain Faber permutations), strategies leaning on developed-ex-US small cap, anything with REIT exposure over 15%. Workable, expect 50 to 100bps annual CAGR drift versus the US backtest.
- Red: Anything depending heavily on active commodity exposure, anything reliant on TIP that needs currency-hedged inflation protection, anything reaching for AVUV-family ETFs as a load-bearing sleeve. Implementable, but the European version is a meaningfully different strategy.
The catalog is filterable on BestFolio by the UCITS-friendliness of each strategy's universe. If you're building TAA from scratch in Europe, the working order is Green first, then Yellow with eyes open, then Red only if you've understood what changes.
What we built to make this less painful
The UCITS Finder inside BestFolio maps every US ticker referenced in any strategy to its closest UCITS substitute, with TER, exchange, and a methodology-similarity score. On any strategy detail page, toggling "Show UCITS" rewrites the asset universe card to the European version, and the backtest re-runs against the substitute basket. For HAA, GEM, and Dalio, the substituted backtests run within a percent of the US version. For strategies in the Yellow and Red tiers, the divergence is visible and quantified, which is the more honest output anyway.
The feedback that triggered this writeup came from a European trusted-tester. His point: every European TAA discussion online stops at "AVUV doesn't have a UCITS clone", as if that single fact resolved the question. What was missing was a per-strategy view of how much of the original you'd actually be getting through the substitution chain. The implementation gap lives in the gradient.
If you're working through this yourself, the BestFolio catalog page now surfaces annualized turnover and CAGR on each card, which is the other lever that matters in Europe. Lower turnover means fewer spread hits, which compounds with cleaner substitution. The strategies that look best on US backtests aren't always the ones you want to actually implement in Europe.